PolyPid Ltd. (PYPD)
2.96
-0.27 (-8.36%)
At close: Mar 03, 2025, 3:58 PM
2.96
0.00%
After-hours: Mar 03, 2025, 03:34 PM EST
Company Description
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs.
Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid Ltd.

Country | IL |
IPO Date | Jun 26, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 59 |
CEO | Dikla Czaczkes Akselbrad |
Contact Details
Address: 18 Hasivim Street Petah Tikva, IL | |
Website | https://www.polypid.com |
Stock Details
Ticker Symbol | PYPD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001611842 |
CUSIP Number | M8001Q118 |
ISIN Number | IL0011326795 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs |
Dikla Czaczkes Akselbrad | Chief Executive Officer & Director |
Jonny Missulawin | Chief Financial Officer |
Ori Warshavsky | Chief Operating Officer - US |
Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
Maria Rubin | Executive Vice President of Operations |
Rivi Lev-ari | Vice President of Human Resource |
Tal Vilnai | General Counsel & Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 26, 2025 | 20-F | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 12, 2025 | 6-K | Filing |
Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 21, 2025 | F-3 | Filing |
Jan 17, 2025 | 6-K | Filing |
Jan 02, 2025 | D | Filing |
Dec 26, 2024 | 6-K | Filing |
Dec 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |